Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.

Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group.

Am J Gastroenterol. 2011 Mar;106(3):460-8; quiz 469. doi: 10.1038/ajg.2010.488. Epub 2011 Jan 4.

2.

Ethnicity and nonalcoholic fatty liver disease.

Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N; Nonalcoholic Steatohepatitis Clinical Research Network Research Group.

Hepatology. 2012 Mar;55(3):769-80. doi: 10.1002/hep.24726.

3.

Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.

Patton HM, Yates K, Unalp-Arida A, Behling CA, Huang TT, Rosenthal P, Sanyal AJ, Schwimmer JB, Lavine JE.

Am J Gastroenterol. 2010 Sep;105(9):2093-102. doi: 10.1038/ajg.2010.152. Epub 2010 Apr 6.

4.

Editorial: Exercise for NAFLD: does intensity matter?

Conjeevaram HS, Tiniakos DG.

Am J Gastroenterol. 2011 Mar;106(3):470-5. doi: 10.1038/ajg.2010.496.

PMID:
21378763
5.

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network.

Hepatology. 2010 Sep;52(3):913-24. doi: 10.1002/hep.23784.

6.

Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.

Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE; NASH Clinical Research Network.

Hepatology. 2012 Jan;55(1):77-85. doi: 10.1002/hep.24706. Epub 2011 Dec 6.

7.

Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.

Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF.

Liver Int. 2011 May;31(5):700-6. doi: 10.1111/j.1478-3231.2011.02482.x. Epub 2011 Feb 20.

PMID:
21457442
8.

Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients.

Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R; NASH CRN.

Hepatology. 2013 Nov;58(5):1644-54. doi: 10.1002/hep.26465. Epub 2013 Oct 2.

9.

Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network.

David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB; NASH CRN Research Group.

Hepatology. 2009 Jun;49(6):1904-12. doi: 10.1002/hep.22868.

10.

The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.

Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N.

J Gastroenterol Hepatol. 2009 Apr;24(4):564-8.

PMID:
19378390
11.

Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD).

Raszeja-Wyszomirska J, Szymanik B, Ławniczak M, Kajor M, Chwist A, Milkiewicz P, Hartleb M.

BMC Gastroenterol. 2010 Jun 28;10:67. doi: 10.1186/1471-230X-10-67.

12.

Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.

Kabbany MN, Conjeevaram Selvakumar PK, Watt K, Lopez R, Akras Z, Zein N, Carey W, Alkhouri N.

Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14.

PMID:
28195177
13.

Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease.

Yilmaz Y, Ayyildiz T, Akin H, Colak Y, Ozturk O, Senates E, Tuncer I, Dolar E.

Gut Liver. 2014 May;8(3):313-7. doi: 10.5009/gnl.2014.8.3.313.

14.

High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery.

Xanthakos SA, Jenkins TM, Kleiner DE, Boyce TW, Mourya R, Karns R, Brandt ML, Harmon CM, Helmrath MA, Michalsky MP, Courcoulas AP, Zeller MH, Inge TH; Teen-LABS Consortium.

Gastroenterology. 2015 Sep;149(3):623-34.e8. doi: 10.1053/j.gastro.2015.05.039. Epub 2015 May 28.

15.

Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.

Kim D, Kim WR, Kim HJ, Therneau TM.

Hepatology. 2013 Apr;57(4):1357-65. doi: 10.1002/hep.26156. Epub 2013 Jan 25.

16.

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.

Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z.

Hepatology. 2011 Jun;53(6):1874-82. doi: 10.1002/hep.24268. Epub 2011 May 14.

PMID:
21360720
17.

Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?

Cengiz M, Candır BA, Yılmaz G, Akyol G, Ozenirler S.

World J Gastroenterol. 2013 Nov 14;19(42):7412-8. doi: 10.3748/wjg.v19.i42.7412.

18.

Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.

Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, Sanderson S, Gawrieh S, Krishnan A, Lindor K.

Hepatology. 2008 Feb;47(2):484-92. doi: 10.1002/hep.22063.

19.

[Clinical and histological features of non-alcoholic fatty liver disease].

Shi JP, Xun YH, Hu CB, Zhang L, Liu H, Lou GQ, Fan JG.

Zhonghua Gan Zang Bing Za Zhi. 2009 Nov;17(11):812-6. Chinese.

PMID:
19958638
20.

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group.

Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11.

Supplemental Content

Support Center